Nonsynonymous C1653T Mutation of Hepatitis B Virus X Gene Enhances Malignancy of Hepatocellular Carcinoma Cells

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. PubMed:33538338. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Li B, Yan C, Zhu J, et al. Anti-PD-1/PD-L1 blockade immunotherapy employed in treating hepatitis B virus infection-related advanced hepatocellular carcinoma: a literature review. Front Immunol. 2020;11:1037. PubMed:32547550.
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The Liver. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–943. PubMed:22424438. doi:10.1016/j.jhep.2011.12.001
   PubMed Web of Science ®Google Scholar
• Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. PubMed:31439937. doi:10.1038/s41575-019-0186-y
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. PubMed:25651787. doi:10.3322/caac.21262
   PubMed Web of Science ®Google Scholar
• Yang HI, Yeh SH, Chen PJ, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst. 2008;100(16):1134–1143. PubMed:18695135. doi:10.1093/jnci/djn243
   PubMedGoogle Scholar
• Shinkai N, Tanaka Y, Ito K, et al. Influence of hepatitis B virus X and core promoter mutations on hepatocellular carcinoma among patients infected with subgenotype C2. J Clin Microbiol. 2007;45(10):3191–3197. PubMed:17652471. doi:10.1128/JCM.00411-07
   PubMed Web of Science ®Google Scholar
• Murakami S. Hepatitis B virus X protein: a multifunctional viral regulator. J Gastroenterol. 2001;36(10):651–660. PubMed:11686474. doi:10.1007/s005350170027
   PubMed Web of Science ®Google Scholar
• Muroyama R, Kato N, Yoshida H, et al. Nucleotide change of codon 38 in the X gene of hepatitis B virus genotype C is associated with an increased risk of hepatocellular carcinoma. J Hepatol. 2006;45(6):805–812. PubMed:17050029. doi:10.1016/j.jhep.2006.07.025
   PubMed Web of Science ®Google Scholar
• Kim YJ, Jung JK, Lee SY, et al. Hepatitis B virus X protein overcomes stress-induced premature senescence by repressing p16(INK4a) expression via DNA methylation. Cancer Lett. 2010;288(2):226–235. PubMed:19656618. doi:10.1016/j.canlet.2009.07.007
   PubMed Web of Science ®Google Scholar
• Guo X, Jin Y, Qian G, et al. Sequential accumulation of the mutations in core promoter of hepatitis B virus is associated with the development of hepatocellular carcinoma in Qidong, China. J Hepatol. 2008;49(5):718–725. PubMed:18801591. doi:10.1016/j.jhep.2008.06.026
   PubMed Web of Science ®Google Scholar
• Kumar V, Jayasuryan N, Kumar R. A truncated mutant (residues 58–140) of the hepatitis B virus X protein retains transactivation function. Proc Natl Acad Sci U S A. 1996;93(11):5647–5652. PubMed:8643631. doi:10.1073/pnas.93.11.5647
   PubMed Web of Science ®Google Scholar
• Xie Y, Liu S, Zhao Y, et al. X protein mutations in hepatitis B virus DNA predict postoperative survival in hepatocellular carcinoma. Tumour Biol. 2014;35(10):10325–10331. PubMed:25034530. doi:10.1007/s13277-014-2331-0
   PubMedGoogle Scholar
• Li SK, Ho SF, Tsui KW, et al. Identification of functionally important amino acid residues in the mitochondria targeting sequence of hepatitis B virus X protein. Virology. 2008;381(1):81–88. PubMed:18805561. doi:10.1016/j.virol.2008.07.037
   PubMed Web of Science ®Google Scholar
• Geng X, Harry BL, Zhou Q, et al. Hepatitis B virus X protein targets the Bcl-2 protein CED-9 to induce intracellular Ca2+ increase and cell death in Caenorhabditis elegans. Proc Natl Acad Sci USA. 2012;109(45):18465–18470. PubMed:23091037. doi:10.1073/pnas.1204652109
   PubMed Web of Science ®Google Scholar
• Lee MO, Choi YH, Shin EC, et al. Hepatitis B virus X protein induced expression of interleukin 18 (IL-18): a potential mechanism for liver injury caused by hepatitis B virus (HBV) infection. J Hepatol. 2002;37(3):380–386. PubMed:12175634. doi:10.1016/S0168-8278(02)00181-2
   PubMed Web of Science ®Google Scholar
• He T, Zhang N, Wang L, et al. GPR43 regulates HBV X protein (HBx)-induced inflammatory response in human LO(2) hepatocytes. Biomed Pharmacother. 2020;123:109737. PubMed:31884344. doi:10.1016/j.biopha.2019.109737
   PubMed Web of Science ®Google Scholar
• Rawat S, Bouchard MJ. The hepatitis B virus (HBV) HBx protein activates AKT to simultaneously regulate HBV replication and hepatocyte survival. J Virol. 2015;89(2):999–1012. PubMed:25355887. doi:10.1128/JVI.02440-14
   PubMed Web of Science ®Google Scholar
• Bouchard MJ, Wang LH, Schneider RJ. Calcium signaling by HBx protein in hepatitis B virus DNA replication. Science. 2001;294(5550):2376–2378. PubMed:11743208. doi:10.1126/science.294.5550.2376
   PubMed Web of Science ®Google Scholar
• Zhu M, Li W, Lu Y, et al. HBx drives alpha fetoprotein expression to promote initiation of liver cancer stem cells through activating PI3K/AKT signal pathway. Int J Cancer. 2017;140(6):1346–1355. PubMed:27925189. doi:10.1002/ijc.30553
   PubMed Web of Science ®Google Scholar
• Park SG, Min JY, Chung C, et al. Tumor suppressor protein p53 induces degradation of the oncogenic protein HBx. Cancer Lett. 2009;282(2):229–237. PubMed:19375220. doi:10.1016/j.canlet.2009.03.019
   PubMed Web of Science ®Google Scholar
• Li Y, Fu Y, Hu X, et al. The HBx-CTTN interaction promotes cell proliferation and migration of hepatocellular carcinoma via CREB1. Cell Death Dis. 2019;10(6):405. PubMed:31138777. doi:10.1038/s41419-019-1650-x
   PubMed Web of Science ®Google Scholar
• Shi Y, Wang J, Wang Y, et al. A novel mutant 10Ala/Arg together with mutant 144Ser/Arg of hepatitis B virus X protein involved in hepatitis B virus-related hepatocarcinogenesis in HepG2 cell lines. Cancer Lett. 2016;371(2):285–291. PubMed:26706415. doi:10.1016/j.canlet.2015.12.008
   PubMed Web of Science ®Google Scholar
• Yun C, Um HR, Jin YH, et al. NF-kappaB activation by hepatitis B virus X (HBx) protein shifts the cellular fate toward survival. Cancer Lett. 2002;184(1):97–104. PubMed:12104053. doi:10.1016/S0304-3835(02)00187-8
   PubMed Web of Science ®Google Scholar
• Wu G, Yu F, Xiao Z, et al. Hepatitis B virus X protein downregulates expression of the miR-16 family in malignant hepatocytes in vitro. Br J Cancer. 2011;105(1):146–153. PubMed:21629246. doi:10.1038/bjc.2011.190
   PubMed Web of Science ®Google Scholar
• Terradillos O, Pollicino T, Lecoeur H, et al. p53-independent apoptotic effects of the hepatitis B virus HBx protein in vivo and in vitro. Oncogene. 1998;17(16):2115–2123. PubMed:9798683. doi:10.1038/sj.onc.1202432
   PubMed Web of Science ®Google Scholar
• Shih WL, Kuo ML, Chuang SE, et al. Hepatitis B virus X protein inhibits transforming growth factor-beta -induced apoptosis through the activation of phosphatidylinositol 3-kinase pathway. J Biol Chem. 2000;275(33):25858–25864. PubMed:10835427. doi:10.1074/jbc.M003578200
   PubMed Web of Science ®Google Scholar
• Liu Y, Lou G, Wu W, et al. Involvement of the NF-κB pathway in multidrug resistance induced by HBx in a hepatoma cell line. J Viral Hepat. 2011;18(10):e439–e446. PubMed:21914061. doi:10.1111/j.1365-2893.2011.01463.x
   PubMed Web of Science ®Google Scholar
• López-Cabrera M, Letovsky J, Hu KQ, et al. Multiple liver-specific factors bind to the hepatitis B virus core/pregenomic promoter: trans-activation and repression by CCAAT/enhancer binding protein. Proc Natl Acad Sci USA. 1990;87(13):5069–5073. PubMed:2367525. doi:10.1073/pnas.87.13.5069
   PubMed Web of Science ®Google Scholar
• Baglieri J, Brenner DA, Kisseleva T. The role of fibrosis and liver-associated fibroblasts in the pathogenesis of hepatocellular carcinoma. Int J Mol Sci. 2019;20(7):1723. PubMed:30959975. doi:10.3390/ijms20071723
   PubMed Web of Science ®Google Scholar
• Hernandez-Gea V, Toffanin S, Friedman SL, et al. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology. 2013;144(3):512–527. PubMed:23313965. doi:10.1053/j.gastro.2013.01.002
   PubMed Web of Science ®Google Scholar
• Moloney JN, Cotter TG. ROS signalling in the biology of cancer. Semin Cell Dev Biol. 2018;80:50–64. PubMed:28587975. doi:10.1016/j.semcdb.2017.05.023
   PubMed Web of Science ®Google Scholar
• Yu F, Wei J, Cui X, et al. Post-translational modification of RNA m6A demethylase ALKBH5 regulates ROS-induced DNA damage response. Nucleic Acids Res. 2021;49(10):5779–5797. PubMed:34048572. doi:10.1093/nar/gkab415
   PubMed Web of Science ®Google Scholar
• Peerzada KJ, Faridi AH, Sharma L, et al. Acteoside-mediates chemoprevention of experimental liver carcinogenesis through STAT-3 regulated oxidative stress and apoptosis. Environ Toxicol. 2016;31(7):782–798. PubMed:26990576. doi:10.1002/tox.22089
   PubMed Web of Science ®Google Scholar
• Takahashi N, Chen HY, Harris IS, et al. Cancer cells co-opt the neuronal redox-sensing channel TRPA1 to promote oxidative-stress tolerance. Cancer Cell. 2018;33(6):985–1003. PubMed:29805077. doi:10.1016/j.ccell.2018.05.001
   PubMed Web of Science ®Google Scholar
• Déliot N, Constantin B. Constantin B Plasma membrane calcium channels in cancer: alterations and consequences for cell proliferation and migration. Biochim Biophys Acta. 2015;1848(10 Pt B):2512–2522. PubMed:26072287. doi:10.1016/j.bbamem.2015.06.009
   PubMed Web of Science ®Google Scholar
• He Y, Lin Y, He F, et al. Role for calcium-activated potassium channels (BK) in migration control of human hepatocellular carcinoma cells. J Cell Mol Med. 2021;25(20):9685–9696. PubMed:34514691. doi:10.1111/jcmm.16918
   PubMed Web of Science ®Google Scholar
• Yang XW, Liu JW, Zhang RC, et al. Inhibitory effects of blockage of intermediate conductance Ca(2+)-activated K (+) channels on proliferation of hepatocellular carcinoma cells. J Huazhong Univ Sci Technolog Med Sci. 2013;33(1):86–89. PubMed:23392713. doi:10.1007/s11596-013-1076-0
   PubMedGoogle Scholar
• Jin M, Wang J, Ji X, et al. MCUR1 facilitates epithelial-mesenchymal transition and metastasis via the mitochondrial calcium dependent ROS/Nrf2/Notch pathway in hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38(1):136. PubMed:30909929. doi:10.1186/s13046-019-1135-x
   PubMed Web of Science ®Google Scholar
• Lei C, Fan Y, Peng X, et al. P2Y11R regulates cytotoxicity of HBV X protein (HBx) in human normal hepatocytes. Am J Transl Res. 2019;11(5):2765–2774. PubMed:31217852.
   PubMed Web of Science ®Google Scholar
• Xie H, Xie D, Zhang J, et al. ROS/NF-κB signaling pathway-mediated transcriptional activation of TRIM37 promotes HBV-associated hepatic fibrosis. Mol Ther Nucleic Acids. 2020;22:114–123. PubMed:32916597. doi:10.1016/j.omtn.2020.08.014
   PubMedGoogle Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–545. PubMed:11229684. doi:10.1016/S0140-6736(00)04046-0
   PubMed Web of Science ®Google Scholar
• Kuroda T, Kitadai Y, Tanaka S, et al. Monocyte chemoattractant protein-1 transfection induces angiogenesis and tumorigenesis of gastric carcinoma in nude mice via macrophage recruitment. Clin Cancer Res. 2005;11(21):7629–7636. PubMed:16278381. doi:10.1158/1078-0432.CCR-05-0798
   PubMed Web of Science ®Google Scholar
• Li X, Yao W, Yuan Y, et al. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Gut. 2017;66(1):157–167. PubMed:26452628. doi:10.1136/gutjnl-2015-310514
   PubMed Web of Science ®Google Scholar
• Shih YT, Wang MC, Zhou J, et al. Endothelial progenitors promote hepatocarcinoma intrahepatic metastasis through monocyte chemotactic protein-1 induction of microRNA-21. Gut. 2015;64(7):1132–1147. PubMed:24939570. doi:10.1136/gutjnl-2013-306302
   PubMed Web of Science ®Google Scholar
• Liu X, Jing X, Cheng X, et al. FGFR3 promotes angiogenesis-dependent metastasis of hepatocellular carcinoma via facilitating MCP-1-mediated vascular formation. Med Oncol. 2016;33(5):46. PubMed:27044356. doi:10.1007/s12032-016-0761-9
   PubMed Web of Science ®Google Scholar
• Finotto S, Siebler J, Hausding M, et al. Severe hepatic injury in interleukin 18 (IL-18) transgenic mice: a key role for IL-18 in regulating hepatocyte apoptosis in vivo. Gut. 2004;53(3):392–400. PubMed:14960523. doi:10.1136/gut.2003.018572
   PubMed Web of Science ®Google Scholar
• Markowitz GJ, Yang P, Fu J, et al. Inflammation-dependent IL18 signaling restricts hepatocellular carcinoma growth by enhancing the accumulation and activity of tumor-infiltrating lymphocytes. Cancer Res. 2016;76(8):2394–2405. PubMed:26893476. doi:10.1158/0008-5472.CAN-15-1548
   PubMed Web of Science ®Google Scholar
• Osaki T, Péron JM, Cai Q, et al. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects. J Immunol. 1998;160(4):1742–1749. PubMed:9469432.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Huang G, Miao H, et al. Apatinib treatment may improve survival outcomes of patients with hepatitis B virus-related sorafenib-resistant hepatocellular carcinoma. Ther Adv Med Oncol. 2020;12(1758835920937422):175883592093742. PubMed:32754228. doi:10.1177/1758835920937422
   Web of Science ®Google Scholar
• Lin JX, Xu YC, Lin W, et al. Effectiveness and safety of apatinib plus chemotherapy as neoadjuvant treatment for locally advanced gastric cancer: a nonrandomized controlled trial. JAMA Netw Open. 2021;4(7):e2116240. PubMed:34241629. doi:10.1001/jamanetworkopen.2021.16240
   PubMed Web of Science ®Google Scholar
• Hu Z, Dong N, Lu D, et al. A positive feedback loop between ROS and Mxi1-0 promotes hypoxia-induced VEGF expression in human hepatocellular carcinoma cells. Cell Signal. 2017;31:79–86. PubMed:28065785. doi:10.1016/j.cellsig.2017.01.007
   PubMed Web of Science ®Google Scholar
• Lin Y, Zhai E, Liao B, et al. Autocrine VEGF signaling promotes cell proliferation through a PLC-dependent pathway and modulates apatinib treatment efficacy in gastric cancer. Oncotarget. 2017;8(7):11990–12002. PubMed:28061477. doi:10.18632/oncotarget.14467
   PubMedGoogle Scholar